Can Merck's New Drugs & Pipeline Ease Keytruda LOE Concerns?

Key Takeaways MRK faces 2028 LOE for Keytruda, which generated $31.7B in 2025, around 55% of pharmaceutical sales.Merck sees $70B in potential non-risk-adjusted commercial opportunities from its pipeline by the mid-2030s.New drugs like Capvaxive posted $759M & Winrevair posted $1.4B sales in 2025 while supporting growth.Merck (MRK) is focusing on driving long-term growth through the newer products and a promising set of pipelines as its blockbuster PD-1 inhibitor, Keytruda, approaches patent expiration in 2 ...